Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 615089, 5 pages
http://dx.doi.org/10.1155/2014/615089
Research Article

The Relationship between Helicobacter pylori and Beta-2 Microglobulin in Humans

1Department of Gastroenterology, Kecioren Teaching and Research Hospital, Kecioren, 06380 Ankara, Turkey
2Department of Internal Medicine, Kecioren Teaching and Research Hospital, Kecioren, 06380 Ankara, Turkey
3Department of Clinical Biochemistry, Kecioren Teaching and Research Hospital, Kecioren, 06380 Ankara, Turkey

Received 10 March 2014; Revised 11 August 2014; Accepted 12 August 2014; Published 27 August 2014

Academic Editor: Jeffrey A. Frelinger

Copyright © 2014 Abdullah Özgür Yeniova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Parsonnet, G. D. Friedman, D. P. Vandersteen et al., “Helicobacter pylori infection and the risk of gastric carcinoma,” The New England Journal of Medicine, vol. 325, no. 16, pp. 1127–1131, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. A. C. Wotherspoon, C. Ortiz-Hidalgo, M. R. Falzon, and P. G. Isaacson, “Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma,” The Lancet, vol. 338, pp. 1175–1176, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Nomura, G. N. Stemmermann, P.-H. Chyou, G. I. Perez-Perez, and M. J. Blaser, “Helicobacter pylori infection and the risk for duodenal and gastric ulceration,” Annals of Internal Medicine, vol. 120, no. 12, pp. 977–981, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Covacci, S. Censini, M. Bugnoli et al., “Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 12, pp. 5791–5795, 1993. View at Google Scholar · View at Scopus
  5. J. W. Yewdell, E. Reits, and J. Neefjes, “Making sense of mass destruction: quantitating MHC class I antigen presentation,” Nature Reviews Immunology, vol. 3, no. 12, pp. 952–961, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. M. Paulsson, P. Wang, P. O. Anderson, S. Chen, R. F. Pettersson, and S. Li, “Distinct differences in association of MHC class I with endoplasmic reticulum proteins in wild-type, and β2-microglobulin- and TAP-deficient cell lines,” International Immunology, vol. 13, no. 8, pp. 1063–1073, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Zijlstra, M. Bix, N. E. Simister, J. M. Loring, D. H. Raulet, and R. Jaenisch, “β2-microglobulin deficient mice lack CD48+ cytolytic T cells,” Nature, vol. 344, no. 6268, pp. 742–746, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Bethea and D. T. Forman, “β2-Microglobulin: Its significance and clinical usefulness,” Annals of Clinical and Laboratory Science, vol. 20, no. 3, pp. 163–168, 1990. View at Google Scholar · View at Scopus
  9. R. Bataille, B. G. M. Durie, and J. Grenier, “Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging,” British Journal of Haematology, vol. 55, no. 3, pp. 439–447, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. E. H. Cooper and T. Plesner, “Beta-2-microglobulin review: its relevance in clinical oncology,” Medical and Pediatric Oncology, vol. 8, no. 4, pp. 323–334, 1980. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Molica, D. Levato, N. Cascavilla, L. Levato, and P. Musto, “Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia,” European Journal of Haematology, vol. 62, no. 2, pp. 117–122, 1999. View at Google Scholar · View at Scopus
  12. S. A. Rashid, E. H. Cooper, A. T. R. Axon, and G. Eaves, “Serum β2-microglobulin in malignant and benign diseases of the stomach and pancreas,” Biomedicine Express, vol. 33, no. 4, pp. 112–116, 1980. View at Google Scholar · View at Scopus
  13. H. Akay, A. Akay, and S. Köklü, “Serum and tissue beta-2 microglobulin levels in patients with Helicobacter pylori infection,” Digestive Diseases and Sciences, vol. 53, no. 2, pp. 358–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Dincer, F. Topal, K. Karaman et al., “Relationship of the intensity of helicobacter pylori and severity of inflammation with beta-2 microglobulin levels in serum according to the updated sydney system,” Southern Medical Journal, vol. 103, no. 11, pp. 1092–1096, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Jackson, J. Britton, S. A. Lewis et al., “A population-based epidemiologic study of helicobacter pylori infection and its association with systemic inflammation,” Helicobacter, vol. 14, no. 5, pp. 108–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Rajasekhar, G. Subramanyam, S. A. Latheef, V. Vanajakshamma, A. Srilatha, and A. Chaudhury, “Infectious aetiology in acute coronary syndromes,” Indian Journal of Medical Microbiology, vol. 20, pp. 83–87, 2002. View at Google Scholar
  17. R. Pellicano, F. Franceschi, G. Saracco, S. Fagoonee, D. Roccarina, and A. Gasbarrini, “Helicobacters and extragastric diseases,” Helicobacter, vol. 14, no. 1, pp. 58–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Zhang, Y. Guo, Y. Ma, and Y. Teng, “Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review,” Chinese Medical Journal, vol. 121, no. 10, pp. 946–951, 2008. View at Google Scholar · View at Scopus
  19. S. Zhang, Y. Guo, Y. Ma, and Y. Teng, “Relationship between the cytotoxin-associated gene-A status of H pylori strains and cerebral infarction in European Caucasians and Chinese Han: a meta-analysis,” World Journal of Gastroenterology, vol. 14, no. 8, pp. 1286–1292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Zissis, A. Afroudakis, G. Galanopoulos et al., “B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?” The American Journal of Gastroenterology, vol. 96, no. 7, pp. 2177–2183, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Wilson, E. Kimura, R. K. Harada et al., “β2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies,” Circulation, vol. 116, no. 12, pp. 1396–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-L. Cheung, K. S. L. Lam, and B. M. Y. Cheung, “Serum β-2 microglobulin concentration predicts cardiovascular and all-cause mortality,” International Journal of Cardiology, vol. 168, pp. 4811–4813, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Liabeuf, A. Lenglet, L. Desjardins et al., “Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients,” Kidney International, vol. 82, no. 12, pp. 1297–1303, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Shinkai, P. H. M. Chaves, Y. Fujiwara et al., “β2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein,” Archives of Internal Medicine, vol. 168, no. 2, pp. 200–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. A. Conz, S. Dante, D. Bernardini, V. Bertoncello, G. La Greca, and P. A. Bevilacqua, “Beta-2-microglobulin and Helicobacter pylori infection in uraemic dialysed patients,” Journal of Gastroenterology and Hepatology, vol. 7, no. 2, pp. 191–193, 1992. View at Publisher · View at Google Scholar · View at Scopus